Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VK0214 · 1 trial · 1 indication
Evaluate the safety and tolerability of multiple oral doses of VK0214 in subjects with AMN
| Arm | Type | Description |
|---|---|---|
| VK0214 Active 20mg | EXPERIMENTAL | 20mg QD |
| VK0214 Active 40mg | EXPERIMENTAL | 40mg QD |
| Placebo | PLACEBO_COMPARATOR | Placebo QD |
| Name | Type | Description |
|---|---|---|
| VK0214 | DRUG | API in capsule |
| Placebo | OTHER | API in capsule |
Inclusion Criteria: * Provide a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study and is willing and able to participate. * Have diagnosis of X-linked adrenoleukodystrophy (X-ALD) by genetic testing and elevated...
VK0214 is an investigational small molecule being developed for the adrenomyeloneuropathy form (AMN) of X-linked adrenoleukodystrophy (X-ALD), a rare inherited disease. It is designed to address this condition, though it is still in clinical development and not yet approved.
VK0214 is being developed by Viking Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker VKTX. The company is conducting clinical research on this investigational drug for the AMN form of X-linked adrenoleukodystrophy.
VK0214 is in Phase 1 clinical development. It has completed a Phase 1 trial, and it remains an investigational drug, meaning it has not been approved by regulatory authorities. Further studies would be needed to establish its safety and efficacy.
VK0214 has one completed Phase 1 clinical trial, identified as NCT04973657, titled "A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN." This randomized, double-blind, placebo-controlled study enrolled 24 participants across the United States, France, Germany, Italy, and the United Kingdom.
VK0214 is the primary name for this investigational drug; no alternative names have been reported. It is a distinct small molecule being studied by Viking Therapeutics for the AMN form of X-linked adrenoleukodystrophy.